Related Experiment Videos
[Cardioxane in pediatric oncohematology]
Voprosy Onkologii
|January 1, 1997
Summary
Dexrazoxane (JCRF-187) demonstrated good tolerance in pediatric cancer patients receiving anthracycline chemotherapy. This cardioprotective agent showed no adverse effects or interference with cancer treatment efficacy.
Area of Science:
- Oncology
- Pharmacology
- Pediatrics
Context:
- Cardioxan (dexrazoxan) is an ethylenediamine tetra-acetic acid analog.
- Pediatric patients with oncohematological conditions often undergo polychemotherapy.
- Anthracycline antibiotics are commonly used in pediatric cancer treatment.
Purpose:
- To evaluate the tolerance of Cardioxan (dexrazoxan) in pediatric cancer patients.
- To assess potential side effects of Cardioxan (dexrazoxan) during chemotherapy.
- To determine if Cardioxan (dexrazoxan) affects the efficacy of cancer treatment.
Summary:
- Dexrazoxan was administered to 37 pediatric patients with acute lymphoblastic leukemia, non-lymphoblastic leukemia, non-Hodgkin's lymphoma, and Hodgkin's disease.
- Patients received polychemotherapy including anthracycline antibiotics concurrently with dexrazoxan.
- No adverse side effects or inhibition of therapeutic effects were observed during the study.
Impact:
- Dexrazoxan appears to be a well-tolerated cardioprotective agent in pediatric cancer patients.
- The findings suggest dexrazoxan can be safely used with anthracycline-based chemotherapy regimens.
- This supports the potential use of dexrazoxan to mitigate cardiotoxicity in pediatric oncology.